MARKET

RVMD

RVMD

Revolution Medicines, Inc.
NASDAQ
161.20
+1.77
+1.11%
After Hours: 164.50 +3.3 +2.05% 18:54 11/20 EST
OPEN
161.61
PREV CLOSE
159.43
HIGH
169.51
LOW
160.22
VOLUME
4.74M
TURNOVER
--
52 WEEK HIGH
224.31
52 WEEK LOW
67.27
MARKET CAP
34.87B
P/E (TTM)
-17.6803
1D
5D
1M
3M
1Y
5Y
1D
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?
The Motley Fool · 3h ago
Midday Fly By: Anthropic drops in day two, Gap reports Q3 earnings beat
TipRanks · 6h ago
Erasca: 'Buy' On Expanded KRAS Targeting ERAS-4001 And Bristol-Myers Squibb Collaboration Tie-Up
Seeking Alpha · 8h ago
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
Benzinga · 9h ago
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Revolution Medicines (RVMD) and Evaxion Biotech (EVAX)
TipRanks · 12h ago
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303
Benzinga · 18h ago
Revolution Medicines presents updated Phase 1/2 data for RASONQUE
TipRanks · 1d ago
Erasca: ERAS-0015 In High Demand, Phase 1 Update On Tap
Seeking Alpha · 1d ago
More
About RVMD
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.

Webull offers Revolution Medicines Inc stock information, including NASDAQ: RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.